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 To investigate the optimal treatment method and risk factor of neck node 32 
metastasis from unknown primary tumors (NUP) treated by radiotherapy.   33 
Methods 34 
 Retrospective case study based on a multi-institutional survey was conducted 35 
by the Japanese Radiation Oncology Study Group. Patients pathologically 36 
diagnosed as having NUP from 1998 to 2007 were identified. Univariate and 37 
multivariate analyses of overall survival (OS), progression free survival (PFS), 38 
neck progression free survival (NPFS) and mucosal progression free survival 39 
(MPFS) were evaluated.  40 
3 
Results  41 
 In total, 130 patients with median age of 65 years were included. Nodal stages 42 
N1, N2a, N2b and N2c were observed for 10, 26, 43, 12 and 39 patients, 43 
respectively. All the patients received radiotherapy (RT) with neck dissection in 44 
60 and with chemotherapy in 67 cases. The median doses to the metastatic 45 
nodes, prophylactic neck and prophylactic mucosal sites were 60.0Gy, 50.4 Gy 46 
and 50.4 Gy, respectively. The median follow-up period for surviving patients 47 
was 42 months. Among 12 patients, occult primary tumors in the neck region 48 
developed after radiotherapy. The 5-year OS, PFS, NPFS and MPFS were 49 
58.1%, 42.4%, 47.3% and 54.9%, respectively. Univariate analysis showed that 50 
lower N stage (N1-2b), non-bulky node (< 6 cm) and negative extracapsular 51 
extension (ECE) status were the factors associated with favorable OS, PFS, 52 
NPFS and MPFS. Radical surgery proved to be a favorable factor of OS, NPFS 53 
and MPFS. On multivariate analysis, lower N stage and negative ECE status 54 
were correlated with improved survival.  55 
Conclusions  56 
 Lower nodal stage and negative ECE status showed a favorable impact on 57 
survival and disease control in patients with NUP treated by radiotherapy.  58 
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Mini Abstract 60 
We conducted a retrospective case study based on multi-institutional survey by 61 
Japanese Radiation Oncology Study Group to assess the efficacy of 62 
radiotherapy for neck node metastasis from unknown primary tumors.  63 
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Introduction 68 
 Neck node metastasis from clinically unknown primary tumors (NUP) accounts 69 
for 2 to 7% of head and neck malignancies1-3. Radiotherapy for NUP is used to 70 
control both macroscopic and microscopic cervical lesions without subsequent 71 
development mucosal lesion. However, the optimal treatment method for NUP 72 
still remains unclear in some respects. The extent of radiotherapy (inclusion of 73 
contralateral cervical lymph node regions and/or mucosal region) and irradiated 74 
dosage is still controversial3-10. Combination of chemotherapy has been 75 
established as the standard therapy of patients with locally advanced head and 76 
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neck cancer, but the role of chemoradiotherapy for NUP has not yet been 77 
established4,11-17. However, it is difficult to conduct randomized or prospective 78 
studies of this disease. The European Organization for Research and Treatment 79 
of Cancer / Radiation Therapy Oncology Group conducted a randomized phase 80 
III trial to compare different radiation therapy regimens in treating NUP patients; 81 
they tried to compare the disease-free survival of NUP patients treated with 82 
selective (i.e. ipsilateral neck) irradiation vs extensive (i.e. bilateral neck, and 83 
pharyngeal and laryngeal mucosa) irradiation30. However, this trial was 84 
prematurely closed because of insufficient patient accrual.  85 
 The purpose of this study was to investigate the optimal treatment method and 86 
risk factor of radiotherapy for NUP by analyzing the results of a retrospective 87 
national survey of radiotherapy for NUP patients treated from 1998 to 2007, 88 
which was conducted by the Japanese Radiation Oncology Study Group 89 
(JROSG).  90 
 91 
Materials and Methods 92 
 The Head and Neck committee of JROSG conducted the multi-institutional 93 
survey by sending questionnaires to 18 institutes in Japan for this retrospective 94 
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study. This study was performed according to the guidelines approved by the 95 
institutional review board of each institute. Patients pathologically diagnosed as 96 
having NUP (squamous cell carcinoma or undifferentiated carcinoma), who were 97 
treated by radiotherapy from 1998 to 2007, were identified. The lymph node 98 
stage was based on the UICC-TNM 7th edition. Those who had distant 99 
metastasis were excluded. The questionnaires included ： age, sex, and 100 
performance status (PS) of the patients; start and end date of radiotherapy; 101 
clinical and pathological N stage; number and maximum size of metastatic lymph 102 
nodes; involved lymph node levels; pathological status (i.e. extracapsular 103 
extension); tumor markers; diagnostic methods (CT, MR, US, PET/CT, 104 
fiberscope); combined therapies (surgery and/or chemotherapy); surgical 105 
procedures and purposes (radical, semiradical, palliative, diagnostic, planned 106 
surgery); chemotherapy contents (concurrent, neoadjuvant, adjuvant, 107 
preoperative, postoperative and alternative); purpose of radiotherapy (radical 108 
and palliative); radiation method, including range and dose of clinical target 109 
volume (local, ipsilateral or bilateral neck and mucosal region); adverse effects; 110 
treatment outcome; salvage therapy; and double cancer. As for target volume, 111 
local irradiation means the irradiation only to the level of the involved nodes 112 
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and ipsilateral irradiation means the irradiation to the prophylactic levels in 113 
addition to the level of involved nodes. No central histological review was 114 
performed for this study. Toxicities were evaluated using National Cancer 115 
Institute Common Toxicity Criteria version 4.0. Severe complications were 116 
defined as those necessitating hospitalization or surgical intervention, and/or 117 
resulting in death.  118 
 Based on the survival data from the questionnaires, 5-year overall survival 119 
(OS), progression free survival (PFS), neck progression free survival (NPFS) 120 
and mucosal progression free survival (MPFS) were estimated by using the 121 
Kaplan-Meier method. OS was defined as the time from treatment initiation to 122 
death from any cause. PFS was defined as the time from treatment initiation to 123 
disease progression or death from any cause. NPFS was defined as the time 124 
from treatment initiation to neck recurrence or death from any cause. MPFS 125 
was defined as the time from treatment initiation to emergence of mucosal 126 
lesion or death from any cause. Univariate and multivariate analysis were 127 
performed to evaluate the factors associated with those survival times; the 128 
factors included PS, extent of clinical target volume, treatment intent, N Stage 129 
(N1-2b vs N2c-N3), lymph node (LN) size, involved LN level (I-III vs IV-VI), 130 
8 
irradiated dose to the involved nodes and prophylactic/mucosal regions, 131 
surgical procedure, ECE status and chemotherapy. 132 
Statistical analysis was performed using JMP Pro version 11 (SAS 133 
Institute Inc., Cary, NC, USA). The log-rank test was used to compare 134 
differences between subgroups. The Chi-square test was used to investigate 135 
the relationship between variables. A p-value of 0.05 indicated significance.  136 
 137 
Results 138 
Patient characteristics and treatment details are summarized in Table 1 and 2. 139 
CT-based three dimensional RT was applied in 70.8% of all the patients. IMRT 140 
was not administered in this series.  141 
 The 5-year OS, PFS, NPFS and MPFS were 58.1%, 42.4%, 47.3% and 54.9%, 142 
respectively (Table 3, Figure 1,2). Recurrence after initial treatment occurred at 143 
1-122 months (median 8 months) in 12 mucosal regions (9 in-field, 3 out-of-field), 144 
29 nodal regions (22 in-field, 4 out-of-field and 3 both in- and out-of-field) and 31 145 
distant metastases. Mucosal recurrences occurred most commonly in the 146 
oropharynx in 6 (4 in-field, 2 out-of-field); other mucosal regions included the 147 
hypopharynx in 2 (all in-field), hypopharynx / cervical esophagus in 1 (in-field), 148 
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oral floor in 1 (in-field), buccal mucosa in 1 (out-of-field) and larynx in 1 (in-field). 149 
Nodal recurrences occurred at 2-67 months (median 9 months) after initial 150 
treatment. The sites of distant metastases were as follows; lung (15), bone (13), 151 
liver (6), pleura (1) and skin (1). 152 
 Univariate analysis showed that lower N stage (N1-2b), non-bulky node (< 6 153 
cm) and ECE negative were factors associated with favorable OS, PFS, NPFS 154 
and MPFS (p<0.05, Table 3). Radical surgery (modified radical neck dissection 155 
or selective neck dissection) also proved to be a factor for favorable OS, NPFS 156 
and MPFS. The median dose for palliative RT was significantly lower than for 157 
radical RT (median 34.0Gy, range 30.0-75.9Gy vs median 60.0Gy, range 158 
12.6-86.8Gy) and the treatment outcome of palliative RT was significantly poor 159 
in OS, PFS and NPFS (Table 2,3). There was no statistical difference in other 160 
factors (extent of clinical target volume, involved LN level, irradiated dose to the 161 
involved nodes and prophylactic/mucosal regions and chemotherapy). 162 
Multivariate analysis, which was conducted for variables that proved to be 163 
prognostic factors by univariate analysis, showed that lower N stage and 164 
negative ECE status was the factor correlated with favorable OS, PFS, NPFS 165 
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and MPFS (p<0.05, Table 4). Radical treatment correlated with favorable OS 166 
and radical surgery was correlated with favorable MPFS. 167 
 As for acute adverse events, grade 3 mucositis was observed in 18 patients 168 
(combined with chemotherapy in 12) and grade 3 dermatitis in 8 (combined with 169 
chemotherapy in 7). As for severe late adverse events, grade 3 laryngeal edema 170 
was observed in 2 patients. Only one patient developed grade 4 brain infarction, 171 
possibly caused by the treatment.  172 
 173 
Discussion 174 
 Radiotherapy, as well as surgery, is considered to be an important option to 175 
control NUP. The optimal method of radiotherapy for NUP had been 176 
controversial for a long time, as it is difficult to conduct randomized or 177 
prospective studies of this rare disease30. Some case studies have revealed 178 
therapeutic outcomes of NUP treated by radiotherapy combined with surgery 179 
and/or chemotherapy, which are summarized in Table 53,6,9,11,16-20. Prognostic 180 
factors for survival are reported to be nodal stages, number of positive nodes, 181 
neck dissection, histopathological grading and ECE3-5,7,9,18,19,21,22. In this series, 182 
the 5-year OS rate was 58.1%, similar to the data in the previous studies. On 183 
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univariate analysis, favorable OS, PFS, NPFS and MPFS were associated with 184 
lower N stage (N1-2b), non-bulky node (< 6 cm) and negative ECE status. On 185 
multivariate analysis, lower N stage and ECE status was correlated with 186 
improved survival. The results are also consistent with those of previous 187 
reports3-5,12,19,21. The current National Comprehensive Cancer Network (NCCN) 188 
guidelines for NUP (Version 1. 2017) provide recommendation for treatment with 189 
neck dissection especially in N1 disease (category 2A). After neck dissection, 190 
treatment strategies are determined by lymph node status. Definitive RT or 191 
observation is recommended in N1 without ECE (category 2A). In the case of N2 192 
or N3 without ECE, definitive RT or chemoradiation therapy is recommended 193 
(category 2B). In the case of ECE, chemoradiation is recommended (category 1). 194 
Definitive radiotherapy without surgery is recommended for N1 (category 2B) 195 
and chemoradiation is recommended for N2 or N3 (category 2B). Induction 196 
chemotherapy followed by systemic chemoradiation therapy is regarded as 197 
category 3.  198 
Unfortunately, there are some limitations in this series. The availability of 199 
FDG-PET was low (31%) and the examination by NBI was not introduced. These 200 
diagnostic procedures have been developed and enabled the detection of early 201 
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head and neck cancers. FDG-PET/CT has demonstrated relatively high 202 
detection rates about 40% of NUP23. The usefulness of NBI with magnifying 203 
endoscopy for detecting the primary site of NUP also has been reported. 204 
Hayashi et al. investigated 46 patients of NUP and 26 lesions were suspected to 205 
be cancerous lesions24. Of 26 patients, 16 lesions in 16 patients (35%, 16/46) 206 
were identified to be squamous cell carcinoma. Another paradigm for the 207 
diagnosis and management of NUP was reported using transitional robotic 208 
surgery. Mehta et al. reported ten patients underwent transoral robotic base of 209 
tongue resection25. All patients underwent a cervical biopsy, PET/CT, formal 210 
endoscopy and bilateral tonsillectomy before this procedure but not identified 211 
primary lesion. In nine of ten patients, pathologic examination revealed invasive 212 
squamous cell carcinoma with a mean diameter of 0.9 cm. 213 
Recently, TNM classification of Malignant Tumours 8th edition was published. 214 
In this new classification, NUP was classified in three categories; EBV or 215 
HPV/p16 negative or unknown, HPV/p16 positive and EBV positive. If EBV was 216 
positive, it was staged as nasopharyngeal carcinomas and if p16 was positive, it 217 
was staged as p16 positive oropharynx carcinomas. Treatment strategy for NUP 218 
is considered to be subdivided by EBV or HPV/p16 status. Unfortunately, we 219 
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would not apply this new TNM classification in present analysis because EBV 220 
and HPV/p16 status was not available in many cases. When we conducted this 221 
study, EBV or HPV/p16 status was not routinely examined. In addition, TNM 222 
classification is a bland-new classification, thus, we could not fully validate the 223 
outcome to reported series.  224 
One of the concerns of NUP treatment is the extent of the irradiation field. It has 225 
been disputed as to whether contralateral neck and/or potential primary site 226 
should be included or not. In our series, there were no significant differences in 227 
OS, PFS, NPFS and MPFS in different irradiation fields. Reddy et al. reported 228 
that subclinical metastases in the contralateral cervical lymph nodes were better 229 
controlled by irradiation, including bilateral neck and pharyngeal mucosa than 230 
ipsilateral neck irradiation (86% vs 56%, p=0.03)10. The occult primary emerged 231 
in 8% after bilateral irradiation and in 44% after ipsilateral irradiation (p=0.0005). 232 
This difference was anticipated to the fact that the mucosal region was contained 233 
in irradiated fields in the bilateral group. Strojan et al. reported the comparison 234 
between involved-field and extended-field in postoperative setting26. In 235 
multivariate analysis, the only factor that influenced locoregional control was the 236 
patients’ age with older patients and the extent of RT field did not influence on 237 
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any outcome. In addition, acute and late toxicity was more common in patients 238 
with extended-field RT. They concluded Involved-field RT, although not superior 239 
over extended-field RT, seems to be a preferred treatment option due to 240 
significantly reduced toxicity and better prospects for successful salvage in case 241 
of contralateral neck recurrence or emergence of mucosal primary in the 242 
pharyngolaryngeal axis. 243 
The rate of metachronous emergence of the primary site was 9.2% (12/130) in 244 
our series; the results were consistent with those of the previous 245 
reports3,6,9,16,18,19. Erkal et al. reported that 12 of 126 patients (10%) developed 246 
squamous cell carcinoma in the head and neck mucosa after initial treatment9. In 247 
the review of Nieder et al., the median rate of emergence of the primary site after 248 
extensive radiotherapy was 9.5% (range 2-13%), whereas it was 8.0% (range 249 
5-44%) after ipsilateral radiotherapy8. As will be discussed later, IMRT with 250 
appropriate mucosal irradiation field settings is considered to lead to better 251 
treatment outcome by controlling the occult mucosal lesions.  252 
In our series, the group that received (modified) radical neck dissection had 253 
better outcomes than the group without neck dissection in terms of OS, NPFS 254 
and MPFS on univariate analysis (p<0.05). Neck dissection followed by 255 
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postoperative radiotherapy is generally recognized as a standard approach, and 256 
also has a clear advantage in evaluation for accurate disease extension and 257 
histopathological features, such as ECE, thus providing additional information to 258 
decide appropriate adjuvant therapeutic strategies such as combination with 259 
chemotherapy. In our series, negative ECE status proved to be a favorable 260 
prognostic factor in OS, PFS, NPFS and MPFS. Coster et al. reported clinical 261 
results of 24 patients with NUP treated with curative resection by neck dissection 262 
or excisional biopsy alone; ECE proved to be an unfavorable prognostic factor of 263 
neck recurrence, cause-specific survival and overall survival18. They concluded 264 
that patients with N1 disease without ECE could be managed by surgery alone, 265 
while patients with N2 or higher nodal stage disease, and/or ECE would be 266 
candidates for postoperative adjuvant radiation therapy.  267 
Although IMRT was not administered in this series, it is considered to be a 268 
promising procedure in treatment for NUP by offering appropriate target volume 269 
coverage while sparing organs-at-risk compared with conventional 270 
radiotherapy11-13,15,20,27,28. Villeneuve et al. reported promising results of NUP 271 
using the IMRT technique11. They treated 25 patients with IMRT by a median 272 
dose of 70 Gy with a radiation field including the bilateral neck and ipsilateral 273 
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pharyngeal mucosa; 17 underwent IMRT for definitive intent, 8 received it for 274 
postoperative setting, and 18 patients received platinum-based concurrent 275 
chemotherapy. With a median follow-up of 38 months, OS, disease-free survival 276 
and locoregional control rates were all 100% at 3 years with no emergence of 277 
primary cancer. Nine patients (36%) developed Grade 2 or greater xerostomia at 278 
6 months, but only 2 (8%) of them developed the same grade of salivary toxicity 279 
after 24 months of follow-up. They concluded concurrent chemoradiotherapy 280 
with IMRT, including bilateral neck and ipsilateral putative pharyngeal mucosa, 281 
as the optimal therapeutic strategy. Janssen et al. reported individualized IMRT 282 
treatment approach to avoid extensive volumes while treating patients without 283 
oncological compromise29. Ipsilateral irradiation was preferred and treatment 284 
fields to the putative mucosal site or the contralateral neck were enlarged based 285 
on individual risk factors including clinical, surgical, histopathological and 286 
imaging information. The 3-year mucosal control rate, nodal control rate, and 287 
distant metastasis free survival were 100, 93, and 88%, respectively and there 288 
were no grade 2 or more late complications. 289 
The role of adding systemic chemotherapy for improving local and distant 290 
control is another important issue. In our present series, the combination of 291 
17 
chemotherapy did not show advantages for improving OS, PFS, NPFS or MPFS. 292 
Argiris et al. reported a series of 25 patients who received concurrent 293 
chemoradiotherapy for N2 or N3 stage NUP17. Although this study was a 294 
retrospective analysis with a small sample size, they concluded that the addition 295 
of systemic chemotherapy may lead to improved locoregional and distant control, 296 
and long-term survival for good performance status patients with stage IV (N2 or 297 
N3) NUP. On the other hand, Chen et al. found no advantage of concurrent 298 
chemotherapy with regard to OS, PFS or locoregional control in a retrospective 299 
analysis of 60 patients treated by radiotherapy, of whom the majority (70%) 300 
underwent neck dissection14. 301 
The all concerns about NUP treatment strategy would be examined along with 302 
the new UICC/AJCC 8th TNM classification, EBV and HPV/p16 status should be 303 
required for accurate staging. Indeed, we do appreciate further investigation 304 
based on the 8th TNM classification should be desirable. 305 
 306 
Conclusion 307 
Our results suggest lower nodal stage, negative ECE status and combination of 308 
radical surgery showed a favorable impact on survival and disease control in 309 
18 
patients with NUP treated by radiotherapy. There were no significant differences 310 
in OS, PFS, NPFS and MPFS in different irradiation fields. 311 
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Table 1. Patient Characteristics 
Characteristic Value 
Age at diagnosis (median) 65  (39-87) 
Gender    
Male 119 (92%) 
Female 11 (8%) 
Histology 
Squamous cell carcinoma 122 (94%) 
Undifferentiated carcinoma 8 (6%) 
Nodal Stage 
N1 10 (8%) 
N2a 26 (20%) 
N2b 43 (33%) 
N2c 12 (9%) 
N3 39 (30%) 
Diagnostic Evaluation 
CT 128 (98%) 
MR 82 (63%) 
FDG-PET 40 (31%) 
Laryngoscopy 96 (74%) 
Tonsillectomy 1 (1%) 
Involved N level 
I 14  (11%) 
II 98  (75%) 
III 39  (30%) 
IV 43  (33%) 
V 14  (11%) 
VI 3  (2%)  
Abbreviations: CT, Computed Tomography  
MR, Magnetic Resonance; FDG-PET, 18-Fluoro- 
deoxyglucose Positron Emission Tomography 
Table 2. Treatment Details 
Treatment Intent 
Radical  17 (13%) 
Palliative  113 (87%) 
Surgical Treatment  
FNA Only 49 (38%) 
Excisional Biopsy 17  (13%) 
Selective Neck Dissection 11 (8%) 
Modified Radical Neck Dissection 53 (41%) 
Chemotherapy 
Yes 66  (51%) 
No 64  (49%) 
Neck Dissection + Chemotherapy 27  (21%) 
Involved Nodal Dose  
Median 60.0 Gy (12.6 – 86.8 Gy) 
Prophylactic Nodal Dose 
Median 50.4 Gy (12.6 - 72.0 Gy) 
Mucosal Dose 
Median 50.4 Gy (12.6 – 71.0 Gy) 
RT Volume 
Local Only 11 (8%) 
Local + Mucosa 2 (2%) 
Ipsilateral Neck 31 (24%) 
Ipsilateral Neck + Mucosa 7 (5%) 
Bilateral Neck 3 (2%) 
Bilateral Neck + Mucosa 76 (58%)  
Mucosal Volume / Irradiated Dose (median dose) 
Nasopharynx 70 (54%) / 12.6-70.0Gy (50.0Gy) 
Oropharynx / Oral Cavity 76 (58%) / 12.6-71.0Gy (50.0Gy) 
Hypopharynx / Larynx  81 (62%) / 12.6-70.0Gy (50.0Gy) 
Cervical Esophagus 51 (39%) / 12.6-70.0Gy (46.0Gy) 
Abbreviations: FNA, Fine Needle Aspiration; RT, Radiotherapy 
Table 3. Univariate analysis for overall survival, progression free survival, neck progression free survival and mucosal progression free survival 
Factor No. of patient OS  PFS  NPFS   MPFS 
% P-Value % P-Value % P-Value % P-Value 
Overall 130 58.1  42.4  47.3  54.9 
Treatment Intent  
Radical 113 60.3  44.2  49.1  56.3 
Palliative 17 30.7 <0.05 29.6 <0.05 34.8 <0.05 41.2 0.17 
PS 
0-1 107 61.8  46.7  52.7 60.0 
2-3 13 40.0 0.13 40.0 0.91 40.0 0.57 44.4 0.48 
N-Stage 
1-2b 79 69.2  51.1  57.3  70.7 
2c-3 51 37.1 <0.01 27.5 <0.01 31.8 <0.01 33.1 <0.01 
N-Size 
< 6 cm 91 66.6  49.7  56.6  61.6 
≥ 6 cm 39 34.9 <0.01 26.6 <0.05 31.2 <0.01 36.9 <0.01 
ECE 
Positive 34 75.5  37.0  41.1  45.5 
Negative 44 53.4 <0.01 56.4 <0.01 62.9 <0.01 71.1 <0.01 
Dose to Involved Nodes (Radical Intent) 
< 50 Gy  8 72.9  60.0  60.0   72.9 
≥ 50 Gy  105 59.3 0.78 43.1 0.93 48.4 0.80 55.0 0.56 
Dose to Prophylactic Nodes (Radical Intent) 
< 50 Gy 46 55.7  34.2  41.8  55.8 
≥ 50 Gy 67 63.3 0.59 50.9 0.08 54.1 0.14 56.7 0.84 
Radical Surgery 
Yes 64 67.2  49.0  43.2  63.9 
No 66 48.5 <0.05 35.6 0.07 38.4 <0.05 45.3 <0.05 
Chemotherapy 
Yes 67 54.7   41.1  46.8  53.9  
No 63 61.4 0.44 43.6 0.63 47.0 0.78 55.4  0.57  
RT Field 
Neck only  46 44.7   31.1   33.8   45.5 
Neck + mucosa  84 65.5  0.24 48.5  0.24 54.8  0.08 59.7 0.46 
Involved Level 
I-III 46 57.6   42.0   47.4   52.3 
IV-VI 84 60.1 0.91 44.1  0.76 49.4  0.90 60.1 0.56 
Abbreviations: OS, Overall Survival; PFS, Progression Free Survival; NPFS, Neck Progression Free Survival; MPFS, Mucosal Progression Free Survival  
PS, Performance Status; RT, Radiotherapy; ECE, Extracapsular Extension  
Table 4. Multivariate analysis for overall survival, progression free survival, neck progression free survival and mucosal progression free survival 
Factor Valuable type OS   PFS   NPFS  MPFS 
  HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value 
Treatment Intent Radical vs Palliative 0.34 0.13-1.00 <0.05 0.44 0.19-1.08 0.07 0.44 0/19-1.08 0.07 0.45 0.17-1.43 0.16 
N stage N1-2b vs N2c-3 0.37 0.20-0.69 <0.01 0.48 0.29-0.80 <0.01 0.48 0.29-0.80 <0.01 0.40 0.22-0.72 <0.01 
Radical surgery Yes vs No 0.44 0.19-1.12 0.08 0.71 0.36-1.50 0.35 0.71 0.36-1.520 0.36 0.39 0.18-0.89 <0.05 
Extracapsular Extension Negative vs Positive 0.30 0.12-0.66 <0.01 0.46 0.25-0.87 0.02 0.46 0.25-0.87 0.02 0.32 0.15-0.67 <0.01 
Abbreviations: OS, Overall Survival; PFS, Progression Free Survival; NPFS, Neck Progression Free Survival; MPFS, Mucosal Progression Free Survival; HR; Hazard Ratio  
  
Table 5. Selected series of cervical patients with squamous cell carcinoma of unknown primary 
Author Year No. of patients Treatment Method (N) 5Y OS (%) Metachronous primaries (%) 
Coster 1992 24 S (24) 66 4 
Grau 2000 273 S (23), R (224), S+R (26) 36 12 
Erkal 2001 126 S+R (70), R (56) 47 10 
Arigiris 2003 25 S+R+C (22), R+C (3) 75  0 
Shehadeh 2006 37 S+R+C (37) NC 3 
Aslani 2007 61 R (41), S+R (20) 79  7 
Klem 2008 21 R (IMRT) (+S), (+C) 85 (2Y) 0 
Ligey 2009 95 R (+S 79), (+C 43) 24  9 
Villeneuve 2012 25 R (IMRT) (+S 8), (+C 18) 100 (3Y) 0 
Janssen 2014 28 R (IMRT) (+S 20), (+C 20) 76 (3Y) 0 
Strojan 2016 126 R (+S 126), (+C 19)  57 9 
Present 2017 130 R (26), (+S 38), (+C 40), (+S+C 26) 58 9 
Abbreviations: OS, Overall Survival; S, Surgery; R, Radiotherapy; C, Chemotherapy; IMRT, Intensity Modulated Radiotherapy; NC, Not Calculated 
 


